Jenny Yune

Jenny Yune

Auto-generated profile, based on publicly available information

Jenny Yune

Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2022 in ACS Chemical Biology
Verified
Journal Article
Closed access
Jose C Bozelli, JrJose C Bozelli, Jr
Jose C Bozelli, Jr
JYJenny Yune
Jenny Yune
SASukhvershjit S. Aulakh
Sukhvershjit S. Aulakh
ZCZihao Cao
Zihao Cao
AFAlexia Fernandes
Alexia Fernandes
RERichard Epand
Richard Epand

30 July 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
POPaolo Oliveira
Paolo Oliveira
AWAizhou Wang
Aizhou Wang
KYKeiji Yamanashi
Keiji Yamanashi
YZYu Zhang
Yu Zhang
PPProdipto Pal
Prodipto Pal
MCMarcelo Cypel
Marcelo Cypel

19 March 2026 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
GSGabriel Siebiger
Gabriel Siebiger
AWAizhou Wang
Aizhou Wang
JYJenny Yune
Jenny Yune
JMJuan Montagne
Juan Montagne
GGGuillermo Garza
Guillermo Garza
MCMarcelo Cypel
Marcelo Cypel
Controlled hypothermic storage of donor organs at 10°C is an emergent clinical standard in lung transplantation due to its superior graft protective effects. Itaconate, a known regulator of cell immunometabolism, has been shown to be upregulated in donor lungs preserved at 10°C for extended periods of static storage versus on ice. We hypothesized that itaconate may be an active agent in donor graft protection against ischemia-reperfusion injury, rather than a byproduct of 10°C graft metabolism. We conducted cell-based screening of multiple formulations and concentrations of itaconate and its derivatives and identified 0.25 mM dimethyl itaconate as the most promising candidate for lung preservation. Lungs from Yorkshire pigs (n = 4/group) were randomized to be flushed with low potassium dextran solution ± 0.25 mM dimethyl itaconate, stored at 4°C for 36 hours to limit endogenous itaconate production, then assessed using ex-vivo lung perfusion. Lungs preserved with dimethyl itaconate had better function, as indicated by lower airway pressures, higher lung compliances, improved perfusate oxygenation, and less edema formation than controls. Perfusate pro-inflammatory cytokines were significantly lower with dimethyl itaconate. Tissue IκBζ levels declined, and dimethyl itaconate prevented tissue oxidative stress after reperfusion. High resolution respirometry indicated no inhibition of succinate dehydrogenase with dimethyl itaconate at 0.25 mM at either hypothermic or normothermic conditions. Dimethyl itaconate safely modulated inflammation and improved lung physiologic performance upon reperfusion, supporting itaconate's protective role in donor-lung preservation.